Protalix BioTherapeutics to Showcase Innovations at Virtual Conference
Protalix BioTherapeutics, Inc. (NYSE American: PLX), a leader in biopharmaceuticals focused on recombinant therapeutic proteins, is gearing up for participation in an upcoming virtual conference. This event, hosted by iAccess Alpha, promises to deliver valuable insights into the company's latest advancements and its pioneering ProCellEx platform, which is key to its protein expression capabilities.
What is the iAccess Alpha Conference?
The iAccess Alpha Virtual Best Ideas Spring Investment Conference is designed to bring together investors and innovative companies like Protalix. The structure of the conference includes engaging webcast presentations, allowing attendees to immerse themselves in the company’s developments. Following the presentations, one-on-one meetings will occur between company representatives and select investors, enhancing the potential for meaningful discussions and connections.
Key Details of the Conference
Scheduled for March 25-26, this virtual event requires participants to register ahead of time to ensure a smooth experience. Protalix encourages attendees to log on at least 15 minutes prior to their session to facilitate necessary software installations. A recording of the presentations will remain accessible for an extended period on the Protalix website post-conference.
Live Presentation Information
The live presentation by Protalix will take place on March 25 at 12:00 p.m. Eastern Daylight Time (EDT). This format allows for real-time interaction and the opportunity to highlight significant milestones in the company’s journey.
Understanding Protalix’s Impact
Protalix stands out in the biopharmaceutical landscape with its innovative ProCellEx technology. This proprietary expression system enables the production of complex therapeutic proteins derived from plant cells. The ability to create proteins in an industrial-scale environment marks a significant advancement in bio-manufacturing, positioning Protalix at the forefront of the industry.
Recent Achievements and Future Goals
One of the landmarks for Protalix came with the FDA approval of its first product manufactured using the ProCellEx system, taliglucerase alfa, aimed at treating Gaucher disease. Global partnerships, such as the one with Pfizer Inc. for this product, underscore Protalix's credibility and trust within the pharmaceutical community.
Furthermore, Protalix's innovative product Elfabrio received approval from both the FDA and the European Medicines Agency, demonstrating the efficacy and safety of its therapeutic offerings. This aligns with Protalix's commitment to addressing unmet medical needs with proprietary treatments.
Future Pipeline and Development
The company is not resting on its laurels. Protalix has a promising pipeline that includes various recombinant proteins targeting significant health challenges. For instance, PRX–115 is designed for uncontrolled gout, while PRX–119 aims to address diseases related to NETs. These candidates highlight Protalix's dedication to expanding its reach in therapeutic areas that impact many lives.
Investor Engagement and Communication
For investors keen to keep abreast of Protalix's progress and developments, the company maintains an open line of communication. Mike Moyer serves as the Managing Director at LifeSci Advisors, and potential investors or interested parties are encouraged to engage fully with the resources available on Protalix's official platforms.
Protalix BioTherapeutics exemplifies innovation in the biopharmaceutical sector, and with the iAccess Alpha Virtual Best Ideas Spring Investment Conference just around the corner, the company is setting itself up for an exhilarating presentation and vibrant discussions ahead.
Frequently Asked Questions
What company is presenting at the virtual conference?
Protalix BioTherapeutics, Inc. will be the presenting company during the iAccess Alpha Virtual Best Ideas Spring Investment Conference.
What is the main focus of Protalix BioTherapeutics?
The company focuses on the development, production, and commercialization of recombinant therapeutic proteins using its proprietary ProCellEx platform.
When will the Protalix presentation take place?
The live presentation is scheduled for March 25 at 12:00 p.m. Eastern Daylight Time.
How can investors participate in the conference?
Investors are encouraged to register for the conference and access the call at least 15 minutes beforehand for a seamless experience.
What notable products has Protalix developed?
Notable products include taliglucerase alfa and Elfabrio, both reflecting the company’s commitment to innovative therapies.
